Hypothesis

Simultaneous pharmacologic inhibition of the NLRP3 inflammasome and activation of NIK‑mediated metabolic signaling will block the transition from progenitor‑like to terminally exhausted CD8+ T cells in aged mice by preserving mitochondrial ROS balance, limiting IL‑18‑driven STAT3 activation, and maintaining TOX‑low/TCF‑1high epigenetic states before DNA methylation locks in exhaustion.

Rationale

Aging drives a feed‑forward loop where NF‑κB–dependent NLRP3 activation releases IL‑18, which exacerbates exhaustion via STAT3‑mediated up‑regulation of PD‑1 and Tim3 [2]. Parallel NIK loss destabilizes hexokinase 2, increases ROS, and pushes CD8+ T cells toward apoptosis and terminal markers [1]. The convergence of inflammatory signaling and metabolic collapse creates a window before TOX‑driven epigenetic barriers and CD39 expression fix exhaustion [4,5]. Targeting only one arm (e.g., NIK overexpression) restores glycolysis but does not quell inflammasome‑derived IL‑18, while NLRP3 inhibition alone reduces inflammation but fails to rescue the metabolic defect that sustains ROS‑mediated NF‑κB activation. Dual intervention should therefore break both arms synergistically.

Predictions

1. In 20‑month‑old mice, combined NLRP3 inhibitor (MCC950) and NIK agonist (or NIK‑overexpressing viral vector) will reduce CD39+PD‑1+Tim3+ terminally exhausted CD8+ T cells by >50% compared with monotherapy or vehicle.
2. The dual treatment will lower intracellular mitochondrial ROS (MitoSOX) and NLRP3‑dependent caspase‑1 activation, while increasing hexokinase 2 stability and glycolytic flux (ECAR) in CD8+ T cells.
3. IL‑18 levels in serum and tumor microenvironment will decrease, accompanied by reduced p‑STAT3 in CD8+ T cells.
4. Epigenetic profiling will show preserved hypomethylation at the Tcf7 locus and reduced TOX binding, maintaining a progenitor‑like chromatin state.
5. Functional assays will reveal restored IFN‑γ production and proliferative capacity upon antigen re‑challenge, surpassing the effects of either intervention alone.

Experimental Design

• Animals: C57BL/6 mice aged 20 months; include young (3 months) controls.
• Groups: (1) Vehicle, (2) MCC950 (NLRP3 inhibitor) 10 mg/kg i.p. thrice weekly, (3) NIK agonist (e.g., CD40L‑Fc) or AAV‑NIK transduction, (4) Combined MCC950 + NIK agonist, (5) Isotype control for biologics.
• Readouts (after 4 weeks):
  • Flow cytometry for CD8+ T‑cell subsets: naïve (CD44loCD62Lhi), progenitor‑exhausted (PD‑1+Tim3+CD39‑), terminal‑exhausted (PD‑1+Tim3+CD39+), with Ki‑67 and Annexin V.
  • Metabolic assays: Seahorse ECAR/OCR, MitoSOX ROS, western blot for hexokinase 2 phosphorylation.
  • Cytokine quantification: ELISA for IL‑18, IFN‑γ, TNF‑α.
  • Phospho‑STAT3 (flow) and NF‑κB p65 nuclear translocation (imaging).
  • ATAC‑seq and bisulfite sequencing on sorted CD8+ T cells to assess Tcf7 accessibility and methylation.
  • In vivo tumor challenge (e.g., B16‑F10 melanoma) to test reinvigoration of anti‑tumor immunity.

Potential Pitfalls and Alternatives

• Compensatory pathways: Chronic NIK activation may trigger non‑canonical NF‑κB–driven inflammation; monitor spleen size and serum cytokines. If observed, titrate NIK agonist dose or use inducible expression.
• Drug delivery: NLRP3 inhibitors have short half‑life; consider nanoparticle encapsulation for sustained release.
• Cell‑specific effects: Use CD8‑specific Cre‑NIK overexpression to exclude effects on myeloid NLRP3.

If dual treatment fails to reduce terminal exhaustion, the hypothesis would be falsified, indicating that additional epigenetic regulators (e.g., DNMT3a) dominate the irreversibility checkpoint, prompting combinatorial approaches with epigenetic modifiers.